1 Department of General Surgery, Oregon Health & Science University, Portland, Oregon2 Pregon Health & Science University–Portland State University School of Public Health, Portland, Oregon3 Knight Cancer Institute Biostatistics, Oregon Health & Science University, Portland, Oregon4 Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, Oregon5 Center for Spatial Systems Biomedicine, Oregon Health & Science University, Portland, Oregon
Checking for direct PDF access through Ovid
BACKGROUND:MicroRNAs are dysregulated in colorectal cancer and subsets correlated with advanced tumor stage and metastasis. Data are lacking on microRNA dysregulation from early to late-stage disease.OBJECTIVE:The purpose of this study was to identify a microRNA signature associated with the primary tumor and metastatic site in stage IV disease and to examine whether the signature is evident in earlier stages.DESIGN:A microRNA profile was generated and then explored in normal colon tissue (n = 5), early stage (stage I and II; n = 10), and late-stage (stage III and IV; n = 14) colorectal primary tumors via polymerase chain reaction to delineate molecular events that may promote colorectal carcinogenesis.SETTING:Genome-wide microRNA expression profiling was performed.PATIENTS:A total of 14 patient-matched stage IV primary colorectal cancer tumors and corresponding liver metastases were included.MAIN OUTCOME MEASURES:MicroRNA array technology was used to identify microRNA expression–predictive metastatic potential in the primary tumor.RESULTS:A distinct 9-member signature group of microRNAs was concurrent in stage IV primary colorectal cancer and their corresponding liver metastases, when compared with surrounding unaffected colon and liver tissue (microRNA-18b, microRNA-93, microRNA-182, microRNA-183, microRNA21, microRNA-486-5p, microRNA-500a, microRNA-552, and microRNA-941). Of the microRNA panel, only microRNA486-5p was differentially expressed in early stage colorectal cancer samples compared with normal tissue (p = 0.001) and additionally differentially expressed between late-stage colorectal cancer samples and normal tissue (p < 0.01).LIMITATIONS:Our microRNA profile was generated in a small subset of patients and will require validation in more samples.CONCLUSIONS:We identified a distinct microRNA signature in primary colon and matched metastatic disease. On additional investigation, 1 microRNA was differentially expressed in both early and late-stage cancer patient samples, and it may herald an early event in colorectal carcinogenesis. This study warrants additional investigation with a larger patient cohort to better understand the effect of microRNAs in carcinogenesis. See Video Abstract at http://links.lww.com/DCR/A723.